Isis Pharmaceuticals, Inc. announced the initiation
of a Phase 2 study
evaluating ISIS-APOCIIIRx in patients with
hypertriglyceridemia......
Ref:http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle_pf&ID=1509616
Med-Chemist : "Quintessential Medicinal Chemistry"
No comments:
Post a Comment